Methamphetamine Disorders

3

Review clinical trials related to Methamphetamine Disorders. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

PrEP Readiness Interventions for Sustained Motivation (PRISM)

This is a hybrid type I randomized controlled trial to test the effectiveness of contingency management (CM) alone versus CM with motivational interviewing (MI) for optimizing entry or re-entry into the HIV prevention or care continua. A total of 400 participants will be randomized to CM (n = 200) or MI+CM (n = 200), all delivered via telehealth. Monthly follow-up assessments will be completed over 12 months to examine effectiveness MI+CM for the primary outcome - filling a pre-exposure prophylaxis (PrEP) or anti-retroviral therapy (ART) prescription (verified using a digital photo). Secondary outcomes will include: self-reported PrEP or ART clinical evaluation by a provider; self-reported meth and other substance use severity (ASSIST), and self-reported receptive and insertive condomless anal sex (CAS).

Participants needed: 400
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Florida International UniversityUpdated: May 7, 2026Locations: 1
Eligibility criteria

18 years or older [+4]

Unwilling or unable to provide informed consent

Status: Not yet recruiting

Reliability, Validity, and Acceptability of a Novel Visual Scale for Estimating Daily Methamphetamine Use Among People Who Use Methamphetamine

PROJECT RESIN: This study is examining the reliability, validity, and acceptability of a novel visual scale for estimating daily methamphetamine use among people who use methamphetamine.

Participants needed: 100
Trial details
Age: 20-40Biological sex: AllType: ObservationalSponsor: Phillip Coffin, MD, MIAUpdated: Mar 11, 2026Locations: 1
Eligibility criteria

Age 20-40 inclusive [+5]

Participant, in the opinion of the investigators, would be unable to complete st...

Status: Recruiting

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

Participants needed: 40
Trial details
Phase: Phase 2Age: 18-55Biological sex: AllType: InterventionalSponsor: Clear Scientific, Inc.Updated: Jan 12, 2026Locations: 1
Eligibility criteria

Healthy participants aged 18 to 55 years, inclusive; [+6]

Estimated glomerular filtration rate <60 mL/min/1.73 m2; [+3]